Skip to main content

Table 2 Meta-analysis results for variants analysed on OncoArray only in the unadjusted analyses in Table 1

From: Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment

Subgroup Variant Chr Position Allelesa AAF Unadjusted meta-analysis Adjusted meta-analysis
HR [95% CI] P value BFDP HR [95% CI] P value BFDP
Grade 3 tumors rs5934618 X 9437463 A/G 0.08 1.32 [1.20,1.45] 1.4E-08 0.01 1.31 [1.18, 1.44]b 7.9E-08 0.05
rs4830644 9434808 A/G 0.08 1.32 [1.20,1.45] 2.1E-08 0.01 1.30 [1.18, 1.43]b 1.7E-07 0.10
rs3810742 9432603 T/C 0.08 1.31 [1.19,1.44] 2.7E-08 0.02 1.29 [1.17, 1.42]b 1.8E-07 0.10
rs4830642 9431786 T/C 0.08 1.31 [1.19,1.44] 2.8E-08 0.02 1.29 [1.17, 1.42]b 2.2E-07 0.12
rs72611496 9434264 G/A 0.08 1.32 [1.20,1.45] 2.3E-08 0.02 1.30 [1.18, 1.43]b 2.5E-07 0.13
ER+ or PR+, and HER2- not treated with CT rs56248395 11 20084391 C/T 0.13 1.53 [1.25,1.89] 5.2E-05 0.97 1.52 [1.24,1.87]c 6.4E-05 0.98
  1. Abbreviations: Chr chromosome, AAF alternative allele frequency, HR hazard ratio, CI confidence interval, BFDP Bayesian False Discovery Probability
  2. Note: BFDP is computed assuming the prior probability of true association equal to 10-4 for all variants, which implies a number of expected true associations in the order of 102. Results with BFDP<0.15 in the adjusted analyses are bolded. aReference/Alternative alleles, bAdjusted for age at diagnosis, lymph node status, tumor size, distant metastases status, ER status, HER2 status, (neo)adjuvant CT, cAdjusted for age at diagnosis, lymph node status, tumor size, and tumor grade